LANABECESTAT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H28N4O
Molecular Weight	412.5267
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO[C@H]1CC[C@@]2(CC3=C(C=C(C=C3)C4=CC(=CN=C4)C#CC)[C@@]25N=C(C)C(N)=N5)CC1

InChI

InChIKey=WKDNQONLGXOZRG-HRNNMHKYSA-N

InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)/t22-,25-,26-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H28N4O
Molecular Weight	412.5267
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27418961 | https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html

AZD-3293 camsylate wider known as Lanabecestat camsylate, a salt of Lanabecestat, a drug that was invented for the treatment of Alzheimer's disease. Lanabecestat inhibits beta-secretase 1 cleaving enzyme (BACE1) thus preventing the buildup of beta-amyloid and help stop the progression of Alzheimer's disease. The drug was in phase III clinical trials, but studies were discontinued because of recommendations by an independent data monitoring committee (IDMC). IDMC concluded that all trials, in early Alzheimer’s disease, and in mild Alzheimer’s disease dementia, were not likely to meet their primary endpoints upon completion and therefore should be stopped for futility.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-secretase 1 21 Target ID: P56817\|\|\|Q9UJT5 Gene ID: 23621.0 Gene Symbol: BACE1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27418961	Inhibitor 8297		0.4 nM [Ki]

PubMed

Title	Date	PubMed
Compounds and Their Use as BACE Inhibitors: Patent Highlight.	2012 Nov 8	24900397
Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs.	2016	27418961

Sample Use Guides

In Vivo Use Guide

Lanabecestat (AZD3293) 20 milligrams (mg) given orally once daily for 104 weeks

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 15:55:46 GMT 2023` Edited by `admin` on `Sat Dec 16 15:55:46 GMT 2023`
Record UNII	X8SPJ492VF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LANABECESTAT

Official Name

English

DISPIRO(CYCLOHEXANE-1,2'-(2H)INDENE-1'(3'H),2''-(2H)IMIDAZOL)-4''-AMINE, 4-METHOXY-5''-METHYL-6'-(5-(1-PROPYN-1-YL)-3-PYRIDINYL)-, (1.ALPHA.,1'R,4.BETA.)-

Systematic Name

English

(1R,1'R,4R)-4-METHOXY-5''-METHYL-6'-(5-(PROP-1-YN-1-YL)PYRIDIN-3-YL)-3'H-- DISPIRO(CYCLOHEXANE-1,2'-INDENE-1',2''-IMIDAZOL)-4''-AMINE

Systematic Name

English

Lanabecestat [WHO-DD]

Common Name

English

LY-3314814

Code

English

(1R,1'R,4R)-4-METHOXY-5''-METHYL-6'-(5-(PROP-1-YN-1-YL)PYRIDIN-3-YL)-3'H-DISPIRO(CYCLOHEXANE-1,2'-INDEN-1',2''-IMIDAZOL)-4''-AMINE

Systematic Name

English

AZD-3293

Code

English

LY3314814

Code

English

LANABECESTAT [USAN]

Common Name

English

AZD3293

Code

English

lanabecestat [INN]

Common Name

English

(1,4-TRANS,1'R)-4-METHOXY-5''-METHYL-6'-(5-(PROP-1-YN-1-YL)PYRIDIN-3-YL)-3'H-DISPIRO(CYCLOHEXANE-1,2'-INDENE-1',2''-IMIDAZOL)-4''-AMINE

Systematic Name

English

Code System Code Type Description

NCI_THESAURUS

C170091